347 related articles for article (PubMed ID: 33578357)
1. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Pujol P; Barberis M; Beer P; Friedman E; Piulats JM; Capoluongo ED; Garcia Foncillas J; Ray-Coquard I; Penault-Llorca F; Foulkes WD; Turnbull C; Hanson H; Narod S; Arun BK; Aapro MS; Mandel JL; Normanno N; Lambrechts D; Vergote I; Anahory M; Baertschi B; Baudry K; Bignon YJ; Bollet M; Corsini C; Cussenot O; De la Motte Rouge T; Duboys de Labarre M; Duchamp F; Duriez C; Fizazi K; Galibert V; Gladieff L; Gligorov J; Hammel P; Imbert-Bouteille M; Jacot W; Kogut-Kubiak T; Lamy PJ; Nambot S; Neuzillet Y; Olschwang S; Rebillard X; Rey JM; Rideau C; Spano JP; Thomas F; Treilleux I; Vandromme M; Vendrell J; Vintraud M; Zarca D; Hughes KS; Alés Martínez JE
Eur J Cancer; 2021 Mar; 146():30-47. PubMed ID: 33578357
[TBL] [Abstract][Full Text] [Related]
2. Finding all BRCA pathogenic mutation carriers: best practice models.
Hoogerbrugge N; Jongmans MC
Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
[TBL] [Abstract][Full Text] [Related]
3. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
[TBL] [Abstract][Full Text] [Related]
4. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
5. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
Eccles DM; Mitchell G; Monteiro AN; Schmutzler R; Couch FJ; Spurdle AB; Gómez-García EB;
Ann Oncol; 2015 Oct; 26(10):2057-65. PubMed ID: 26153499
[TBL] [Abstract][Full Text] [Related]
7. Genetic testing in ovarian cancer - clinical impact and current practices.
Knabben L; Imboden S; Mueller MD
Horm Mol Biol Clin Investig; 2019 Oct; 41(3):. PubMed ID: 31577534
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Riahi A; Chabouni-Bouhamed H; Kharrat M
Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
[TBL] [Abstract][Full Text] [Related]
9. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
10.
Talwar V; Rauthan A
Indian J Cancer; 2022 Mar; 59(Supplement):S56-S67. PubMed ID: 35343191
[TBL] [Abstract][Full Text] [Related]
11. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
Vos S; van Diest PJ; Moelans CB
Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
[TBL] [Abstract][Full Text] [Related]
12. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
13. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D
Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410
[TBL] [Abstract][Full Text] [Related]
14. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
16. Germline Genetic Testing: What the Breast Surgeon Needs to Know.
Plichta JK; Sebastian ML; Smith LA; Menendez CS; Johnson AT; Bays SM; Euhus DM; Clifford EJ; Jalali M; Kurtzman SH; Taylor WA; Hughes KS
Ann Surg Oncol; 2019 Jul; 26(7):2184-2190. PubMed ID: 30941656
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
18. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer.
Kwong A; Chen J; Shin VY; Ho JC; Law FB; Au CH; Chan TL; Ma ES; Ford JM
Cancer Genet; 2015 Sep; 208(9):448-54. PubMed ID: 26271414
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
Gori S; Barberis M; Bella MA; Buttitta F; Capoluongo E; Carrera P; Colombo N; Cortesi L; Genuardi M; Gion M; Guarneri V; Incorvaia L; La Verde N; Lorusso D; Marchetti A; Marchetti P; Normanno N; Pasini B; Pensabene M; Pignata S; Radice P; Ricevuto E; Sapino A; Tagliaferri P; Tassone P; Trevisiol C; Truini M; Varesco L; Russo A;
Crit Rev Oncol Hematol; 2019 Aug; 140():67-72. PubMed ID: 31176273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]